News

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...
Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...
Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...
Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...
Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...
Bristol Myers Squibb (NYSE:BMY) has tapped Cristian Massacesi, as executive vice president, chief medical officer, and head of development, effective August 1, 2025. Massacesi most recently served as ...
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
Speaking during the Fierce JPM Week virtual conference, Bristol's CMO, Samit Hirawat, said the company's deucravacitinib is a novel TYK2 inhibitor "with a very specific downstream effect of ...
PRINCETON, N.J.—Samit Hirawat, the Executive Vice President and Chief Medical (TASE: PMCN) Officer of Bristol Myers Squibb Co. (NYSE:BMY), recently made a significant purchase of the company's stock.
Samit Hirawat So for -- as I said earlier, for both of the studies, so CC-220, or iberdomide, we're looking at the readout of that fourth line plus population data within this year.
PRINCETON, N.J.—Samit Hirawat, the Executive Vice President and Chief Medical (TASE: PMCN) Officer of Bristol Myers Squibb Co. (NYSE:BMY), recently made a significant purchase of the company's ...